Measures of disease activity in glaucoma

Area of Science:

• Ophthalmology
• Medical Diagnostics
• Biotechnology

Background:

• Glaucoma is a leading cause of irreversible blindness globally, impacting quality of life and incurring significant economic costs.
• Early detection and intervention are vital to prevent vision deterioration and maintain patient well-being.
• Current diagnostic methods, while effective, highlight the need for novel tools for earlier and more precise glaucoma identification.

Purpose of the Study:

• To review current clinical tests for glaucoma diagnosis, including intraocular pressure, visual field tests, and optical coherence tomography.
• To highlight advanced technologies and their potential as novel surrogate endpoints for glaucoma.
• To explore the applications of artificial intelligence in glaucoma diagnosis and prediction.

Main Methods:

• Comprehensive review of existing and emerging glaucoma diagnostic technologies.
• Analysis of functional and structural changes in glaucomatous eyes.
• Evaluation of tear fluid biomarker analysis and advanced imaging techniques.
• Exploration of artificial intelligence algorithms for ophthalmic data analysis.

Main Results:

• Current methods effectively describe functional and structural changes but have limitations in early detection.
• Tear fluid biomarkers and advanced imaging offer promising novel surrogate endpoints.
• Artificial intelligence demonstrates potential as a post-diagnostic tool for analyzing ophthalmic test results.
• Integration of multiple variables, including imaging and AI, is key for future diagnostic evaluations.

Conclusions:

• Novel technologies, including tear fluid analysis, advanced imaging, and artificial intelligence, are crucial for advancing glaucoma detection.
• Future glaucoma diagnostics will likely involve assessing a wider range of variables for earlier and more accurate identification.
• Continued development in these areas is essential for improving patient management and preventing vision loss.